Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9

被引：1

作者：

Williams, Stephen B. ^{[1
]}

Kamat, Ashish M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA

来源：

EUROPEAN UROLOGY | 2016年 / 69卷 / 06期

关键词：

CARCINOMA;

D O I：

10.1016/j.eururo.2016.01.053

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E121 / E122

页数：2

共 6 条

[1] Reply to Stephen B. Williams and Ashish M. Kamat's Letter to the Editor re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol 2016;69:60-9
Sylvester, Richard
Gontero, Paolo
Oddens, Jorg
EUROPEAN UROLOGY, 2016, 69 (06) : E123 - E124
[2] EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin
Cambier, Samantha
Sylvester, Richard J.
Collette, Laurence
Gontero, Paolo
Brausi, Maurizio A.
van Andel, George
Kirkels, Wim J.
Da Silva, Fernando Calais
Oosterlinck, Willem
Prescott, Stephen
Kirkali, Ziya
Powell, Philip H.
de Reijke, Theo M.
Turkeri, Levent
Collette, Sandra
Oddens, Jorg
EUROPEAN UROLOGY, 2016, 69 (01) : 60 - 69
[3] Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin Editorial Comment
Chang, Sam S.
JOURNAL OF UROLOGY, 2017, 198 (01): : 39 - 40
[4] Re: Paolo Gontero, Richard Sylvester, Francesca Pisano, et al. Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients. Eur Urol 2015; 67:74-82
Montorsi, Francesco
Gandaglia, Giorgio
EUROPEAN UROLOGY, 2015, 67 (01) : E7 - E7
[5] Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766-73
Cai, Tommaso
Luciani, Lorenzo Giuseppe
Malossini, Gianni
EUROPEAN UROLOGY, 2010, 57 (06) : E57 - E57
[6] Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guerin, and Bacillus Calmette-Guerin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766-73 Reply
Sylvester, Richard J.
Brausi, Maurizio A.
Kirkali, Ziya
de Reijke, Theo M.
EUROPEAN UROLOGY, 2010, 57 (06) : E58 - E59

← 1 →